S'abonner

The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract - 15/03/24

Doi : 10.1016/j.jinf.2024.01.017 
Linlin Xie a, 1, Gengyan Luo b, 1, Zhongzhou Yang b, Wei-chen Wu b, Jintao Chen c, Yuting Ren c, Zhikun Zeng a, Guangming Ye a, Yunbao Pan a, Wen-jing Zhao b, Yao-qing Chen d, Wei Hou c, Yanni Sun e, Deying Guo b, Zifeng Yang f, Jun Li g, Edward C. Holmes h, Yirong Li a, , Liangjun Chen a, , Mang Shi b,
a Wuhan Research Center for Infectious Diseases and Tumors of the Chinese Academy of Medical Sciences/Hubei Engineering Center for Infectious Disease Prevention, Control and Treatment/Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China 
b State key laboratory for biocontrol, Shenzhen Key Laboratory of Systems Medicine for inflammatory diseases, School of Medicine, Shenzhen campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China 
c State Key Laboratory of Virology/Department of Laboratory Medicine/Hubei Province Key Laboratory of Allergy and Immunology, School of Basic Medical Sciences/Zhongnan Hospital, Wuhan University, Wuhan, China 
d School of Public Health (Shenzhen), Shenzhen campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China 
e Department of Electrical Engineering, City University of Hong Kong, Hong Kong, China 
f State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 
g Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China 
h Sydney Institute for Infectious Diseases, School of Medical Sciences, The University of Sydney, Sydney, Australia 

Corresponding authors.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Objectives

The respiratory tract is the portal of entry for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a variety of respiratory pathogens other than SARS-CoV-2 have been associated with severe cases of COVID-19 disease, the dynamics of the upper respiratory microbiota during disease the course of disease, and how they impact disease manifestation, remain uncertain.

Methods

We collected 349 longitudinal upper respiratory samples from a cohort of 65 COVID-19 patients (cohort 1), 28 samples from 28 recovered COVID-19 patients (cohort 2), and 59 samples from 59 healthy controls (cohort 3). All COVID-19 patients originated from the earliest stage of the epidemic in Wuhan. Based on a modified clinical scale, the disease course was divided into five clinical disease phases (pseudotimes): “Healthy” (pseudotime 0), “Incremental” (pseudotime 1), “Critical” (pseudotime 2), “Complicated” (pseudotime 3), “Convalescent” (pseudotime 4), and “Long-term follow-up” (pseudotime 5). Using meta-transcriptomics, we investigated the features and dynamics of transcriptionally active microbes in the upper respiratory tract (URT) over the course of COVID-19 disease, as well as its association with disease progression and clinical outcomes.

Results

Our results revealed that the URT microbiome exhibits substantial heterogeneity during disease course. Two clusters of microbial communities characterized by low alpha diversity and enrichment for multiple pathogens or potential pathobionts (including Acinetobacter and Candida) were associated with disease progression and a worse clinical outcome. We also identified a series of microbial indicators that classified disease progression into more severe stages. Longitudinal analysis revealed that although the microbiome exhibited complex and changing patterns during COVID-19, a restoration of URT microbiomes from early dysbiosis toward more diverse status in later disease stages was observed in most patients. In addition, a group of potential pathobionts were strongly associated with the concentration of inflammatory indicators and mortality.

Conclusion

This study revealed strong links between URT microbiome dynamics and disease progression and clinical outcomes in COVID-19, implying that the treatment of severe disease should consider the full spectrum of microbial pathogens present.

Le texte complet de cet article est disponible en PDF.

Highlights

The URT microbiome exhibits complex and changing patterns during COVID-19.
A series of microbes are identified to be associated with more severe disease stages.
There are strong links between URT microbiome dynamics and disease progression.

Le texte complet de cet article est disponible en PDF.

List of abbreviations : SARS-CoV-2, MERS-CoV, HSV-1, COVID-19, ICU, ECMO, PERMANOVA, RF, RPM, rpoB, gyrB, ERG11, NLR, NEUT, LYMPH, WBC, PLT, HGB, ALT, AST, IL-6, LDH, CRP, DD, PCT, SAA

Keywords : SARS-CoV-2, COVID-19, Upper respiratory tract, Microbiome, Meta-transcriptomics


Plan


© 2024  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 88 - N° 3

Article 106118- mars 2024 Retour au numéro
Article précédent Article précédent
  • Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance
  • Meredith Leston, Willam Elson, Jose M. Ordóñez-Mena, Debasish Kar, Heather Whitaker, Mark Joy, Nia Roberts, F.D. Richard Hobbs, Simon de Lusignan
| Article suivant Article suivant
  • Burden of child mortality from malaria in high endemic areas: Results from the CHAMPS network using minimally invasive tissue sampling
  • Ikechukwu U. Ogbuanu, Kephas Otieno, Rosauro Varo, Samba O. Sow, Julius Ojulong, Babatunde Duduyemi, Dickens Kowuor, Carrie Jo Cain, Emily A. Rogena, Dickens Onyango, Victor Akelo, Beth A. Tippett Barr, Feiko terKuile, Karen L. Kotloff, Milagritos D. Tapia, Adama Mamby Keita, Jane Juma, Nega Assefa, Nardos Assegid, Yenework Acham, Lola Madrid, J. Anthony G. Scott, Shams El Arifeen, Emily S. Gurley, Sana Mahtab, Ziyaad Dangor, Jeannette Wadula, Jeanie Dutoit, Shabir A. Madhi, Inácio Mandomando, David Torres-Fernandez, Milton Kincardett, Rita Mabunda, Portia Mutevedzi, Zachary J. Madewell, Dianna M. Blau, Cynthia G. Whitney, Aaron M. Samuels, Quique Bassat, for the CHAMPS consortium

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.